{
    "nct_id": "NCT03123783",
    "official_title": "A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma",
    "inclusion_criteria": "* Histologically or cytologically confirmed, immunotherapy naÃ¯ve or PD-1/PD-L1 pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment. Subjects may be treatment naive or could have received one prior platinum based chemotherapy for non-small cell lung cancer and subjects with a documented activating mutation (e.g., EGFR, ALK, ROS) must also have received the appropriate therapy and progressed\n* Histologically or cytologically confirmed unresectable or metastatic melanoma that progressed during treatment with an anti-PD-1/PD-L1 therapy and had confirmation of PD>=4 weeks later. Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy.\n* Measurable disease by RECIST 1.1\n* ECOG performance status of 0 or 1\n* Adequate bone marrow, liver and kidney function\n* Negative pregnancy test for women of child bearing potential\n* Agreement to use effective methods of contraception per the protocol requirements\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Previous exposure to any immunomodulatory agents (e.g., anti- CD40, anti-PD-1/PD-L1, anti-CTLA-4, IDO inhibitors) except PD-1/PD-L1 targeting agents in the subsets of patients that must have previous treatment with anti-PD-1/PD-L1 therapy\n* Second malignancy (solid or hematologic) within the past 3 years except locally curable cancers that have been apparently cured\n* Active, known, clinically serious infections within the 14 days prior to first dose of investigational product\n* Use of systemic corticosteroids or other systemic immunosuppressive drugs\n* Active, known or suspected autoimmune disease\n* History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis\n* History of interstitial lung disease\n* History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for subjects with metastatic melanoma or NSCLC.",
    "miscellaneous_criteria": ""
}